Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Operating Expenses: 2014-2025

Historic Operating Expenses for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to -$210.8 million.

  • Ascendis Pharma A's Operating Expenses fell 33.85% to -$210.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.3 million, marking a year-over-year increase of 9.71%. This contributed to the annual value of $647.4 million for FY2024, which is 11.24% down from last year.
  • Per Ascendis Pharma A's latest filing, its Operating Expenses stood at -$210.8 million for Q3 2025, which was down 203.70% from $203.2 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Operating Expenses registered a high of $203.2 million during Q2 2025, and its lowest value of -$210.8 million during Q3 2025.
  • Over the past 3 years, Ascendis Pharma A's median Operating Expenses value was $170.5 million (recorded in 2024), while the average stood at $114.1 million.
  • Per our database at Business Quant, Ascendis Pharma A's Operating Expenses surged by 281.65% in 2021 and then crashed by 182.63% in 2024.
  • Ascendis Pharma A's Operating Expenses (Quarterly) stood at $130.4 million in 2021, then climbed by 29.27% to $168.5 million in 2022, then decreased by 1.13% to $166.6 million in 2023, then rose by 2.30% to $170.5 million in 2024, then plummeted by 33.85% to -$210.8 million in 2025.
  • Its Operating Expenses stands at -$210.8 million for Q3 2025, versus $203.2 million for Q2 2025 and $197.4 million for Q1 2025.